Publication: Magyar Közlöny
Issue: MK-2009-67 (Year: 2009, Number: 67)
Era: 2004-2010
Section: szóló 267/2006. (XII. 20.) Korm. rendelet
Paragraph Index: 399

(30) days following receipt of all the information by WADA. (b) WADA can, on its own initiative, undertake a review at any time. 7.12 If the decision regarding the granting of a TUE is reversed by WADA upon review, the reversal shall not apply retroactively and shall not disqualify the Athlete’s results during the period that the TUE had been granted and shall take effect no later than fourteen (14) days following notification of the decision to the Athlete. 7.13 Use of inhaled Beta-2 Agonists: – The Use of inhaled formoterol, salbutamol, salmeterol, terbutaline reflects current clinical practice. The Use of these substances should be declared on ADAMS where reasonably feasible and in accordance with the Code as soon as the product is used and must as well be declared on the Doping Control form at the time of Testing. Failure to declare will be taken into account in the result management process in particular in case of application for a Retroactive TUE. – Athletes using the substances listed above by inhalation must have a medical file justifying this Use and meeting the minimum requirements outlined in Annex 1. Depending upon the category of the Athlete, the medical file will be evaluated as follows: – For all Athletes included in an International Federation Registered Testing Pool a regular TUE approved before the Use of the substance. – For Athletes participating in an International Event but who are not included in an International Federation Registered Testing Pool either a TUE, or a Retroactive TUE in the case of an Adverse Analytical Finding, in accordance with the rule of the International Federation or of the Major Event Organization. – For national-level Athletes who are not included in an International Federation Registered Testing Pool, whether or not they are part of a national Registered Testing Pool, either a TUE, or a Retroactive TUE in the case of an Adverse Analytical Finding, in accordance with the rules of the National Anti-Doping Organization. – No Retroactive TUE will be granted if the requirements of Annex 1 are not met meaning that any Adverse Analytical Finding reported by the laboratory in these circumstances will result in an anti-doping rule violation. – Any Athlete may apply for a TUE at any time if they wish. – Any Athlete who has applied for a TUE or a Retroactive TUE and who was denied such TUE may not use the substance without the prior granting of a TUE (no Retroactive TUE will be permitted). 2009/67. szám 8.0 Declaration of Use Process 8.1 It is acknowledged that some substances included on the List of Prohibited Substances are used to treat medical conditions frequently encountered in the athlete population. For monitoring purposes, these substances, for which the route of administration is not prohibited, will require a simple declaration of use. These are strictly limited to: Glucocorticosteroids used by non systemic routes, namely intraarticular, periarticular, peritendinous, epidural intradermal injections and inhaled route. 8.2 For the mentioned substances, the declaration of Use should be done through ADAMS where reasonably feasible and in accordance with the Code by the Athlete at the same time as the Use starts. This declaration should mention the diagnosis, the name of the substance, the dose undertaken, the name and the contact details of the physician. In addition, the Athlete must declare the Use of the substance in question on the Doping Control form. 9.0 Clearinghouse 9.1 Anti-Doping Organizations are required to provide WADA with all TUEs approved for Athletes who are part of a national or international Registered Testing Pool, and all supporting documentation, in accordance with section 7. 9.2 The declarations of use should be available to WADA (ADAMS). 9.3 The clearinghouse shall guarantee strict confidentiality of all the medical information. 10.0 Transitional Provision Abbreviated Therapeutic Use Exemptions (ATUEs) delivered prior to December 31 2008, shall remain governed by the 2005 TUE Standard. These ATUEs shall remain valid after January 1 2009, until the earliest of: (a) The date on which they are cancelled by the competent TUEC following review in accordance with art. 8.6 of the 2005 TUE Standard; (b) Their expiry date as mentioned on the ATUE; (c) December 31 2009. Annex 1: Minimal requirements for the medical file to be used for the TUE process in the case of asthma and its clinical variants The file must reflect current best medical practice to include:

Source: https://magyarkozlony.hu/hivatalos-lapok/a0826574a9cdc69a4202c6f3c150095e9d6bf297/dokumentumok/9bade261b3624216c43ae6a991faba20b201acc1/letoltes